Pipeline

Development Stage and Anticipated Milestones TherapeuticIndication AntibodyProgram IND Enabling Phase 1 Phase 2 Phase 3 Rosnilimab(PD-1 depleterand agonist) Initial P2 dataQ4 2025 ANB033(CD122 antagonist) Inflammatory Diseases Ulcerative Colitis Rheumatoid Arthritis P1 initiatedR&D eventH2 2025 P1 initiated ANB101(BDCA2 modulator) Inflammatory Diseases Updated clinical andtranslational dataJune 2025 Immune Cell Modulators